Conmy

Conmy

terazosin

Manufacturer:

Taiwan Biotech

Distributor:

New Smart Formulae
Concise Prescribing Info
Contents
Terazosin HCl
Indications/Uses
HTN & symptomatic benign prostatic hyperplasia (BPH).
Dosage/Direction for Use
BPH Initially 1 mg at bedtime, subsequently increase stepwise to 2, 5 or 10 mg once daily at 7 days intervals. HTN Initially 1 mg at bedtime increasing gradually at 7 days intervals according to patient's response, up to 20 mg daily. Usual maintenance dose: 2-10 mg daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Not for treatment of heart failure caused by mechanical obstruction ie, aortic or mitral valve stenosis, pulmonary embolism & restrictive pericardial disease.
Special Precautions
Postural hypotension & syncope in association w/ the 1st dose or 1st few days of therapy. Patients w/ BPH should be examined prior to start of therapy to rule out the presence of prostate carcinoma. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn.
Adverse Reactions
Dizziness, lightheadedness, palpitations; hypotension, postural hypotension, syncope, vertigo.
Drug Interactions
Possibility of developing significant hypotension w/ verapamil & other antihypertensives.
MIMS Class
Drugs for Bladder & Prostate Disorders / Other Antihypertensives
ATC Classification
G04CA03 - terazosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Presentation/Packing
Form
Conmy tab 2 mg
Packing/Price
100's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in